Neurocrine Biosciences
NBIX
418 hedge funds and large institutions have $8.63B invested in Neurocrine Biosciences in 2020 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 189 increasing their positions, 109 reducing their positions, and 68 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 109
3% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 68
0% more funds holding
Funds holding: 418 → 418 (0)
1.88% less ownership
Funds ownership: 98.17% → 96.28% (-1.9%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
22% less capital invested
Capital invested by funds: $11.1B → $8.63B (-$2.51B)
70% less call options, than puts
Call options by funds: $40.5M | Put options by funds: $136M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$88.8M |
| 2 |
Renaissance Technologies
New York
|
+$76.9M |
| 3 |
HM
HealthCor Management
New York
|
+$66.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$39M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$211M |
| 2 |
BlackRock
New York
|
-$80M |
| 3 |
PA
Perceptive Advisors
New York
|
-$68.6M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$45.5M |
| 5 |
Jennison Associates
New York
|
-$41.7M |
NBIX Hedge Fund Activity: Q3 2020 in Review
418 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2020, worth a combined $8.63B — down 22% from $11.1B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new NBIX positions and 68 closed out — a net gain of 2 holders — while 189 added to existing stakes and 109 trimmed.
The largest buyer was Congress Asset Management, opening a new position worth an estimated $88.8M. The largest seller was Capital International Investors, cutting an estimated $211M.
- 418 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $8.63B of Neurocrine Biosciences stock for Q3 2020, down 22% quarter-over-quarter.
- 70 funds opened new Neurocrine Biosciences positions in Q3 2020 and 68 closed out, a net change of +2 holders.
- The largest Neurocrine Biosciences buyer in Q3 2020 was Congress Asset Management, an estimated $88.8M added.
- The largest Neurocrine Biosciences seller in Q3 2020 was Capital International Investors, an estimated $211M sold.
Based on aggregated 13F filings for Q3 2020.